Displaying drugs 14601 - 14625 of 15153 in total
Lacutamab
Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).
Investigational
Anti-GD2 monoclonal antibody 3F8
Anti-GD2 monoclonal antibody 3F8 is under investigation in clinical trial NCT00089258 (Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment).
Investigational
Minretumomab
Experimental
AMP-224
Investigational
Anise oil
Experimental
Alpinia officinarum leaf
Experimental
LV-SMENP Vaccine
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).
As of August 2020, this vaccine...
Investigational
Cedar leaf oil
Experimental
Cajuput oil
Experimental
Nutmeg oil
Experimental
Adagloxad simolenin
Adagloxad simolenin is under investigation in clinical trial NCT03562637 (Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC).
Investigational
Simlukafusp alfa
RO6874281 is under investigation in clinical trial NCT03193190 (A Study of Multiple Immunotherapy-based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-pancreatic Cancer)).
Investigational
Antithrombin gamma
Antithrombin gamma is under investigation in clinical trial NCT04182373 (KW-3357 Study in Patients With Early Onset Severe Preeclampsia).
Investigational
Cemdisiran
Cemdisiran is under investigation in clinical trial NCT03841448 (A Study of Cemdisiran in Adults With Immunoglobulin a Nephropathy (Igan)).
Investigational
Befovacimab
Investigational
INVAC-1
INVAC-1 is under investigation in clinical trial NCT03265717 (DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (Htert), Invac-1 in Chronic Lymphocytic Leukemia).
Investigational
IONIS-HBVRx
IONIS-HBVRx is under investigation in clinical trial NCT04544956 (A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B).
Investigational
B27PD
B27PD is under investigation in clinical trial NCT01195948 (Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis).
Investigational
Rinucumab
Rinucumab is under investigation in clinical trial NCT02418754 (Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-related Macular Degeneration (AMD)).
Investigational
siG12D LODER
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
STX-100
STX-100 is under investigation in clinical trial NCT01371305 (STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)).
Investigational
BGB-DXP593
BGB-DXP593 is a SARS-CoV-2 neutralizing antibody. It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)) by BeiGene.
Investigational
Camidanlumab tesirine
Camidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).
Investigational
Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine
Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated to the hepatitis B surface antigen . Virus-like particles (VLPs) are protein-based vaccines that stimulate high immune responses because of the VLPs’...
Investigational
AG0302-COVID19
Sponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
Investigational
Displaying drugs 14601 - 14625 of 15153 in total